Publications, Pharmaceutical

Comparison of Pulmonary Deposition for Single and Multidose Dry Powder Inhalers with Indacaterol and Glycopyrrolate

An inhaled combination of indacaterol maleate and glycopyrronium bromide is routinely prescribed for the management of chronic obstructive pulmonary disease.

This paper describes work to determine the suitability of using a multi-unit dose dry powder inhaler to deliver this formulation in place of the single unit dose device associated with current commercial products. The results of in vitro and in silico studies indicate no difference in aerodynamic distribution or regional deposition respectively, between the two devices. This suggests comparable pulmonary performance and potential for interchangeability. The multi-unit dry powder inhaler offers practical advantages, such as eliminating the need to handle capsules, and requires a reduced inspiratory flow for effective drug delivery, making it the more patient-friendly option.

Download Publication
25 Jun 2020

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

12 Jul 2022

Digital Health and Digital Therapeutics: Where are we heading and...

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
12 Jul 2022

How pMDIs are transforming Asthma and COPD treatments

Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Jun 2022

Supporting Patients and HCPs with New Digital Technology

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 14
Back To Top